Sinovac Biotech Ltd.

387 articles with Sinovac Biotech Ltd.

• Sinovac Holds 2017 Annual General Meeting of Shareholders

  2/7/2018

  Sinovac Biotech announced today that it held its 2017 Annual General Meeting of Shareholders on Tuesday, February 6, 2018 in Beijing, PRC.

• Sinovac Schedules 2017 Annual Meeting of Shareholders

  12/29/2017

  Sinovac announced today that it will hold its 2017 Annual Meeting of Shareholders on Tuesday, February 6, 2018 at 9:00 a.m.

• Sinovac Biotech Receives Positive Decision on its Hepatitis A Vaccine From WHO

  12/27/2017

  Sinovac Biotech announced today that it has received a positive decision from the WHO on the acceptability, in principle, of its Healive, a hepatitis A vaccine product, for purchase by United Nations agencies.

• Sinovac Reports Unaudited First Half of 2017 Financial Results

  12/1/2017

  Sinovac Biotech announced today that it reported its unaudited financial results for the six months ended June 30, 2017.

• Sinovac Biotech Cures Nasdaq Filing Deficiency

  12/1/2017

  In the letter, Nasdaq indicated that the Company is in compliance with all applicable listing standards.

• Sinovac Biotech Announces Update on Nasdaq Matters

  11/30/2017

  Sinovac announced today that the Nasdaq Hearings Panel granted the Company's request to extend the stay of suspension in trading of the Company's common shares pending a hearing on January 11, 2018 and issuance of a final Panel decision.

• Sinovac Files 2016 Annual Report on Form 20-F and Reports Unaudited Fourth Quarter 2016 Financial Results

  11/27/2017

  Quarterly sales from continuing operations were $31.4M compared to $23M in the prior year period, an increase of 36.7%.

• Sinovac Biotech Announces Request Hearing Before Nasdaq Hearings Panel

  11/8/2017

  As reported on November 3, 2017, the Company received a delisting determination letter from the Staff of the Listing Qualifications Department (the"LQ Staff") of The Nasdaq Stock Market, Inc.

• Sinovac Biotech Announces Receipt of Delisting Determination Letter from Nasdaq

  11/6/2017

  The Company has not yet filed the 2016 Annual Report.

• Sinobioway Group Consortium Provides Update On Acquiring Sinovac Biotech Ltd. At The Purchase Price Of $8 Per Share

  9/29/2017

• Sinovac Biotech Ltd. Announces Early Positive Results For Chickenpox Vaccine

  9/27/2017

• Sinovac Biotech Ltd. Reports Preliminary Top-Line Results From Phase III Clinical Trial For Varicella Vaccine Candidate Against Chickenpox

  9/25/2017

• Sinovac Biotech Ltd. Announces Certain Updates Relating To Delayed Filing Of Annual Report On Form 20-F

  8/14/2017

• Sinobioway Consortium Provides Update On Acquiring Sinovac Biotech Ltd. At The Purchase Price Of $8 Per Share

  8/10/2017

• Sinovac Biotech Ltd. Goes Private in $401.8 Million Deal

  6/26/2017

• Sinovac Biotech Ltd. Announces Receipt Of NASDAQ Letter And Delayed Filing Of Annual Report On Form 20-F

  5/17/2017

• Sinovac Biotech Ltd. Reports Announces Filing Extension For 2016 Annual Report

  5/1/2017

• Sinovac Biotech Ltd. Amends Shareholder Rights Plan

  3/24/2017

• Sinovac Biotech Ltd. Responds To Recent Report

  12/27/2016

• Sinovac Biotech Ltd. CEO Reportedly Bribed Chinese FDA, Buyout Offers Could Be in Jeopardy

  12/22/2016